KFDA to issue caution over prescription of weight loss pill sibutramine

Published: 2010-02-02 07:00:00

Updated: 2010-02-02 07:00:00

Doctors will be advised to restrain the prescription of the controversial anti-obesity drug sibutramine in patients with cardiovascular disease, according to the Korea Food and Drug Administration.

The measures come following a recommendation from the Central Pharmaceutical Affairs Review Comm...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK